explore -WSS

explore

author：focus 2025-09-03 11:52:01 - browse：626

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： First Opinion Podcast: What happens when kids become caregivers?

entertainment

WSS

First Opinion Podcast: What happens when kids become caregivers?

Insmed lung disease drug hits target in key Phase 3 trial

Making AI in medicine accessible to smaller, and rural hospitals

Do more moles mean more problems? Not so, says new study

Childbirth

Study: People of West African ancestry at greater risk of cardiac amyloidosis

hotspot

explore

hotspot

Alkermes shareholders re

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Cancer drug shortages should be causing more outrage

Focused ultrasound for uterine fibroids: an uphill battle

Activists slam private health insurers over coverage restrictions

Adam's Biotech Scorecard: Do Sarepta's exon

Medicare details structure of new drug price negotiation program

Health insurers say they are turning to AI to cut costs, improve care

Moonlake's readout produced a cash windfall. Risks remain

Startling documents reveal new facets of Sacklers' opioid empire

entertainment

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Lab trade group sues FDA to halt regulation of lab

Readout LOUD podcast: What to know about H5N1 bird flu

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Akili, maker of video game for ADHD, to be acquired for 34 million

Elevance, private equity launch primary care company

explore

entertainment

entertainment

focus